Fundraising FoxAxial Biotherapeutics
Boston, US · Founded 2013 · Delaware corporation · 5 known investors
Find your way into Axial Biotherapeutics
Sign up to see every warm intro you have to Axial Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axial Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Axial Biotherapeutics was founded in 2013 by SARKIS K. MAZMANIAN.
SK
SARKIS K. MAZMANIANFounder
DH
RC
Ronald C. Renaud Jr.Named on SEC filing
HW
Henry WolfNamed on SEC filing
Board
JC
JAMES C. BLAIRBoard director
MD
Investors · 5
Domain AssociatesreportedPrinceton · $200K – $15M
How we know: funding news · Not right? Tell us
Longwood FundreportedBoston
How we know: board seat on SEC Form D · funding news · Not right? Tell us
OneVenturesreportedSydney · $3.3M – $13.2M
How we know: press coverage · Not right? Tell us
Seventure PartnersreportedParis
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$109.8M disclosed across 7 rounds · 2016–2025
▶$19.4MraisedFeb 2025 · 29 investors · PharmaceuticalsRule 506(b)
▶$19.4MraisedFeb 2025 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- SARAH MEIBUSCHDirector
- SCOTT C. BRUNDirector
- REBECCA SENTERExecutive Officer
- NORA FREYDirector
- A. STEWART CAMPBELLExecutive Officer, Director
- Michele CuculluDirector
- SARKIS K. MAZMANIANDirector
- Offering amount
- $22M
- Amount sold
- $19.4M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedOct 2023 · 35 investors · PharmaceuticalsRule 506(b)
▶$11.1MraisedOct 2023 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY E. YOUNGExecutive Officer
- SARAH MEIBUSCHDirector
- SCOTT C. BRUNDirector
- RICHARD P. ALDRICHDirector
- MARK OHORIDirector
- JAMES C. BLAIRDirector
- SAKAE ASANUMADirector
- A. STEWART CAMPBELLExecutive Officer, Director
- NORA FREYDirector
- SARKIS K. MAZMANIANDirector
- Offering amount
- $24M
- Amount sold
- $11.1M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.4MraisedOct 2021 · 38 investors · PharmaceuticalsRule 506(b)
▶$27.4MraisedOct 2021 · 38 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- SAKAE ASANUMADirector
- RICHARD P. ALDRICHDirector
- NORA FREYDirector
- SCOTT BRUNDirector
- SARKIS K. MAZMANIANDirector
- JEFFREY E. YOUNGExecutive Officer
- A. STEWART CAMPBELLExecutive Officer, Director
- MARK OHORIDirector
- JAMES C. BLAIRDirector
- SARAH MEIBUSCHDirector
- RONALD C. RENAUD JR.Director
- Offering amount
- $37.8M
- Amount sold
- $27.4M
- Finders' fees
- $500K
- Placement agents
- JMP SECURITIES LLC
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedMay 2020 · 21 investors · PharmaceuticalsRule 506(b)
▶$7.8MraisedMay 2020 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY YOUNGExecutive Officer
- SAKAE ASANUMADirector
- RICHARD P. ALDRICHDirector
- SCOTT BRUNDirector
- SARKIS K. MAZMANIANDirector
- Ronald C. Renaud Jr.Director
- JAMES C. BLAIRDirector
- Eric De La FortelleDirector
- DAVID H. DONABEDIANExecutive Officer, Director
- Henry WolfDirector
- Offering amount
- $8M
- Amount sold
- $7.8M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJun 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJun 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JAMES C. BLAIRDirector
- DAVID H. DONABEDIANExecutive Officer, Director
- SARKIS K. MAZMANIANDirector
- RICHARD P. ALDRICHDirector
- Henry WolfDirector
- Eric De La FortelleDirector
- SAKAE ASANUMADirector
- JEFFREY YOUNGExecutive Officer
- Ronald C. Renaud Jr.Director
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedNov 2018 · 36 investors · PharmaceuticalsRule 506(b)
▶$20MraisedNov 2018 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY YOUNGExecutive Officer
- SARKIS K. MAZMANIANDirector
- Henry WolfDirector
- JAMES C. BLAIRDirector
- RICHARD P. ALDRICHDirector
- Ronald C. Renaud Jr.Director
- DAVID H. DONABEDIANExecutive Officer, Director
- Offering amount
- $28M
- Amount sold
- $20M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$19.1MraisedJun 2017 · 16 investors · BiotechnologyRule 506(b)
▶$19.1MraisedJun 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SARKIS K. MAZMANIANDirector
- JAMES C. BLAIRDirector
- Ronald C. Renaud Jr.Director
- DAVID H. DONABEDIANExecutive Officer
- MICHELLE DIPPDirector
- Henry WolfDirector
- Offering amount
- $19.1M
- Amount sold
- $19.1M
- Minimum investment
- $150K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Axial Biotherapeutics?
- Axial Biotherapeutics was founded by SARKIS K. MAZMANIAN in 2013.
- Who are Axial Biotherapeutics's investors?
- Axial Biotherapeutics's investors include Domain Associates, Domain Partners, Longwood Fund, OneVentures, Seventure Partners.
- How much funding has Axial Biotherapeutics raised?
- Axial Biotherapeutics has disclosed $109.8M raised across 7 rounds.
- Where is Axial Biotherapeutics headquartered?
- Axial Biotherapeutics is headquartered in Boston, US.